Germany Coronary Drug-Eluting Balloon Market Insight
Published: 26 May 2026 | Report Format: Electronic (PDF)
Germany Coronary Drug Eluting Balloon Market, opportunities will be driven by growing prevalence of cardiovascular disease, the increasing trend of minimally invasive cardiology procedures.
Germany Coronary Drug-Eluting Balloon Market Insights and Forecasts to 2035
- In 2025, the Germany Coronary Drug-Eluting Balloon Market stood at USD 78.8 Million, establishing a strong base for future growth.
- It is anticipated to expand at a CAGR of 7.3% over 2025 to 2035, supported by increasing percutaneous coronary interventions.
- The market is projected to reach USD 159.7 Million by 2035, reflecting continuous long-term growth.
Notable Insights for the Germany Coronary Drug-Eluting Balloon Market
- On the basis of product type, paclitaxel-coated balloons prevail in the global market, representing approximately 72-76% market share in 2025. Paclitaxel-coated balloons are popular with cardiologists from Germany due to their high effectiveness in preventing restenosis and enhancing vascular healing performance.
- On the basis of application, in-stent restenosis treatment accounts for approximately 46-50% share in the global market in 2025. Drug-eluting balloons are more prevalent in managing cases of restenosis due to the fact that drug-eluting balloons are less prone to further stent insertion complications.
- Over 68% of procedures conducted by interventional cardiologists at advanced German centres incorporate innovations in minimally invasive vascular treatments in order to ensure better patient recovery performance.
- More than 64% of all cardiovascular device innovations and investments in Germany focus on innovations in drug-coated balloon technology.
Download the eBook (ToC)
Research Methodologies Used to Analyze the Germany Coronary Drug-Eluting Balloon Market
Germany coronary drug-eluting balloon market sizing is accomplished using both primary and secondary research methods. Primary research involves discussions with interventional cardiologists, hospital administrators, medical device companies, and other healthcare professionals in Germany. Secondary research uses analysis of medical device companies' annual financial reports, regulatory databases, clinical trials, published articles, healthcare journals, and cardiovascular therapies industry sources. In addition, market modelling, competitive intelligence, and pricing analysis methodologies have been employed to provide accurate market projections and insights.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organisations/companies involved within the Germany coronary drug-eluting balloon market, along with a comparative evaluation primarily based on their product offerings, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product approvals, clinical trial developments, strategic partnerships, mergers & acquisitions, and catheter technology innovations. This allows for the evaluation of the overall competition within the market.
Top Companies in Germany Coronary Drug-Eluting Balloon Market
- B. Braun Melsungen AG
- BIOTRONIK
- Medtronic
- Boston Scientific Corporation
- Philips Healthcare
- Terumo Corporation
- Cardionovum GmbH
- Cook Medical
- Concept Medical
- iVascular
Recent Developments:
- In February 2025, BIOTRONIK broadened its range of coronary interventions with more sophisticated drug-coated balloons targeting treatment of complex lesions and enhanced vascular healing performance.
- In September 2024, B. Braun Melsungen AG reinforced its cardiovascular catheter solutions range via novel clinical collaborations and innovations in minimally invasive therapy within European healthcare markets.
Market Segmentation:
Germany Coronary Drug-Eluting Balloon Market, By Product Type
- Paclitaxel-Coated Balloons
- Sirolimus-Coated Balloons
- Others
Germany Coronary Drug-Eluting Balloon Market, By Application
- In-Stent Restenosis
- Small Vessel Disease
- Bifurcation Lesions
- De Novo Coronary Lesions
Germany Coronary Drug-Eluting Balloon Market, By End User
- Hospitals
- Cardiac Catheterization Laboratories
- Speciality Cardiac Centers
- Ambulatory Surgical Centers
Expert Views:
Strong growth is anticipated in Germany's drug-eluting balloon market, as it faces favourable conditions such as a growing burden of cardiovascular diseases, an increase in demand for minimally invasive coronary procedures, and constant innovations in drug-coated balloon and catheter technology.
Author: Komal and Radhika By Spherical Insights and Consulting